Key result
Natriuretic peptide and troponin screening emerges as key for diagnosing and preventing HF in diabetes.
Why the study?
Heart failure is an often-unnoticed complication of diabetes, prompting a review of current evidence and management practices of biomarker screening for heart failure in people with diabetes.
This webinar summary highlights the emerging role of biomarker screening to detect unrecognized heart failure in patients with diabetes.
Hypothesis-generating for biomarker screening in diabetes; prospective trials needed before clinical adoption.
The Biomarkers for the Diagnosis of Heart Failure in Diabetes webinar was hosted by Diabetes Technology Society on September 20, 2023, with the objective to review current evidence and management practices of biomarker screening for heart failure in people with diabetes. The webinar discussed (1) the four stages of heart failure, (2) diabetes and heart failure, (3) natriuretic peptide and troponin for diagnosing heart failure in diabetes, (4) emerging composite and investigational biomarkers for diagnosing heart failure, and (5) prevention of heart failure progression. Experts in heart failure from the fields of clinical chemistry, cardiology, and diabetology presented data about the importance of screening for heart failure as an often-unnoticed complication of people with type 1 and type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Aaron et al. (2024) conducted a review in Heart failure in diabetes. Biomarker screening was evaluated. Biomarker screening, including natriuretic peptide and troponin, was reviewed as an important approach for diagnosing and preventing heart failure in patients with type 1 and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: